| Next 10 |
Ad
OCGN News and Press Ocugen Inc.
News | Ocugen, Inc. (NASDAQ:OCGN)
-
2025-06-16 09:38:57 ET More on Ocugen Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript Ocugen signs license deal with Korean company for gene therapy Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit Se...
-
MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendmen...
-
MALVERN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present at the 2025 BIO International Convention at the Boston Convention & Ex...
-
2025-06-05 09:32:01 ET More on Ocugen Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit Crispr Therapeutics, Clover Health among healthcare stocks to join Russel...
-
Upfront fees and near-term development milestone payments totaling up to $11 million Sales milestones of $150 million or more in first 10 years of commercialization Royalties equaling 25% of net sales Ocugen to manufacture and supply OCU400 MALVERN, Pa., June 05, 2...
-
2025-05-28 09:50:11 ET More on related stocks: MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition Ginkgo Bioworks: Cost-Cutting Efforts Aren't Enough Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript) Ocugen wins ...
-
2025-05-28 09:35:41 ET More on related stocks: Tempus AI: Firing On All Cylinders Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide Sell Tempus AI Stock Before The Cooldown Hits Ocugen wins FDA rare pediatric disease status for genetic eye disorder tr...
-
2025-05-27 09:44:43 ET More on Ocugen Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript Ocugen outlines 2025 milestones for gene therapy programs with BLA filings on track Ocugen Q4 2024 Earnings Preview...
-
MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the United States Food and Drug Administration (U.S. FDA) has granted Rare Pediatric Disease Designa...
-
2025-05-09 10:05:08 ET More on Ocugen Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript Ocugen Q4 2024 Earnings Preview Ocugen aligns with FDA on confirmatory study for OCU410ST Seeking Alpha...
Stock Information
Get OCGN Alerts
News, Short Squeeze, Breakout and More Instantly...
Ocugen, Inc. Company Name:
OCGN Stock Symbol:
NASDAQ Market:
-0.86% G/L:
$1.09 Last:
5,176,555 Volume:
$1.17 Open:
$1.09 Close:
Ocugen, Inc. Website:
Ad
-
2025-05-08 18:48:18 ET Ocugen, Inc. (OCGN) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 5.00%. The average open to low on the day of earnings was -5.13%. The average open to close on ...
-
2025-05-08 18:43:19 ET Ocugen, Inc. (OCGN) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in OCGN stock price following earnings has averaged ±2.26% , with a median of 1.62%. The sin...
-
2025-03-05 13:15:17 ET Image source: The Motley Fool. Ocugen (NASDAQ: OCGN) Q4 2024 Earnings Call Mar 05, 2025 , 8:30 a.m. ET Operator Continue reading